Cargando…

CPT-11/bevacizumab for the treatment of refractory brain metastases in patients with HER2–neu-positive breast cancer

Nervous system relapse of patients with advanced HER2–neu-positive breast cancer is an increasing problem, with one-third of women developing brain metastases. Standard therapies using steroids, surgery and radiotherapy do not provide a lasting response. We evaluated CPT-11 and bevacizumab, which ca...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sengupta, S., Rojas, R., Mahadevan, A., Kasper, E., Jeyapalan, S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2015
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4664841/ https://www.ncbi.nlm.nih.gov/pubmed/26634139 http://dx.doi.org/10.1093/omcr/omv010

Ejemplares similares

Apatinib + CPT-11 + S-1 for treatment of refractory brain metastases in patient with triple-negative breast cancer: Case report and literature review
por: Hu, Ting, et al.
Publicado: (2018)

Breast Cancer and Her-2/Neu
por: Sherwood, Roy
Publicado: (2005)

Clinical and prognostic profile of Her2neu positive (non-luminal) intrinsic breast cancer subtype: comparison with Her2neu positive luminal breast cancers
por: Hashmi, Atif Ali, et al.
Publicado: (2018)

Long-term remission of a Her2/neu positive primary breast cancer under double monoclonal antibody therapy with trastuzumab and bevacizumab
por: Königsberg, Robert, et al.
Publicado: (2014)

HER-2/neu diagnostics in breast cancer
por: Carney, Walter P, et al.
Publicado: (2007)

Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer
por: Salkeni, Mohamad Adham, et al.
Publicado: (2021)

Factors Influencing Lymph Node Positivity in HER2/neu+ Breast Cancer Patients
por: Englander, Katherine, et al.
Publicado: (2023)

Active immunization with a Her-2/neu-targeting Multi-peptide B cell vaccine prevents lung metastases formation from Her-2/neu breast cancer in a mouse model
por: Tobias, Joshua, et al.
Publicado: (2022)

Practical consensus recommendations regarding the management of HER2 neu positive early breast cancer
por: Bahl, A., et al.
Publicado: (2018)

Practical consensus recommendations regarding the management of HER2 neu positive metastatic breast cancer
por: Basade, M., et al.
Publicado: (2018)

Global metabolite profiling analysis of lipotoxicity in HER2/neu-positive breast cancer cells
por: Baumann, Jan, et al.
Publicado: (2018)

Combining losartan with radiotherapy increases tumor control and inhibits lung metastases from a HER2/neu-positive orthotopic breast cancer model
por: Li, Wende, et al.
Publicado: (2021)

Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours.
por: DiGiovanna, M. P., et al.
Publicado: (1996)

Anti-Her-2/neu antibody induces apoptosis in Her-2/neu overexpressing breast cancer cells independently from p53 status
por: Brodowicz, T, et al.
Publicado: (2001)

Single-Institute Review of HER-2/Neu-Positive Invasive Lobular Breast Carcinoma in an Arab Population
por: Osmani, Asif Husain, et al.
Publicado: (2021)

Computational model to explore the endocrine response to trastuzumab action in HER-2/neu positive breast cancer
por: Wang, Fuzhang, et al.
Publicado: (2022)

Updated recommendations from the Canadian National Consensus Meeting on HER2/neu testing in breast cancer
por: Hanna, W., et al.
Publicado: (2007)

Freund's vaccine adjuvant promotes Her2/Neu breast cancer
por: Cotroneo, Michelle S, et al.
Publicado: (2009)

Reproducibility in the automated quantitative assessment of HER2/neu for breast cancer
por: Keay, Tyler, et al.
Publicado: (2013)

Adjuvant effect of HER-2/neu-specific adenoviral vector stimulating CD8(+) T and natural killer cell responses on anti-HER-2/neu antibody therapy for well-established breast tumors in HER-2/neu transgenic mice
por: Chen, Y, et al.
Publicado: (2011)

Antibody–Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors
por: McNamara, Blair, et al.
Publicado: (2023)

The Clinical Importance of the Heterogeneity of HER2 neu
por: Davila, Enrique, et al.
Publicado: (2010)

Complete pathological response in patients with locally advanced cancer of breast and positive Her2/neu with neoadjuvant chemotherapy
por: Cedeño, Heidy, et al.
Publicado: (2007)

Palmitate-induced ER stress increases trastuzumab sensitivity in HER2/neu-positive breast cancer cells
por: Baumann, Jan, et al.
Publicado: (2016)

Bevacizumab in Combination with Modified FOLFOX6 in Heavily Pretreated Patients with HER2/Neu-Negative Metastatic Breast Cancer: A Phase II Clinical Trial
por: Li, Ting, et al.
Publicado: (2015)

Risk factors for the development of brain metastases in patients with HER2-positive breast cancer
por: Maurer, Christian, et al.
Publicado: (2018)

Brain Metastases in HER2-Positive Breast Cancer: Current and Novel Treatment Strategies
por: Garcia-Alvarez, Alejandro, et al.
Publicado: (2021)

Combination of radiotherapy and targeted therapy for HER2-positive breast cancer brain metastases
por: Yang, Xiaojing, et al.
Publicado: (2023)

Pyrotinib-based treatments in HER2-positive breast cancer patients with brain metastases
por: Ma, Xiaoping, et al.
Publicado: (2022)

Adjuvant Intravitreal Bevacizumab Injection for Choroidal and Orbital Metastases of Refractory Invasive Ductal Carcinoma of the Breast
por: Lin, I-Hung, et al.
Publicado: (2021)

HER2/neu expression correlates with vasculogenic mimicry in invasive breast carcinoma
por: Liu, Tieju, et al.
Publicado: (2013)

Detection of HER-2/neu-positive circulating epithelial cells in prostate cancer patients
por: Ady, N, et al.
Publicado: (2004)

Brain metastases in Asian HER2-positive breast cancer patients: anti-HER2 treatments and their impact on survival
por: Yap, Y S, et al.
Publicado: (2012)

Phosphorylation of Ser(78 )of Hsp27 correlated with HER-2/neu status and lymph node positivity in breast cancer
por: Zhang, Daohai, et al.
Publicado: (2007)

Change in HER-2/neu Status from Negative to Positive following Treatment in Breast Cancer: A Case Report
por: Sivarajan, Lakshmi, et al.
Publicado: (2011)

Cytotoxic T-cell precursor frequencies to HER-2 (369 – 377) in patients with HER-2/neu-positive epithelial tumours
por: Sotiropoulou, P A, et al.
Publicado: (2003)

How we treat HER2-positive brain metastases
por: Stavrou, E., et al.
Publicado: (2021)

HER 2/neu protein expression in colorectal cancer
por: Schuell, B, et al.
Publicado: (2006)

HER-2/neu Testing and Therapy in Gastroesophageal Adenocarcinoma
por: Moelans, Cathy B., et al.
Publicado: (2010)

Anti-HER2/Neu passive-aggressive immunotherapy
por: Mortenson, Eric D, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_r6e8c96oa6ho96np4165vslkp7